NMNH

NMNH

Название продукта NMNH (Reduced Nicotinamide Mononucleotide)
Other Names NMNH; Reduced NMN; Dihydronicotinamide mononucleotide
Номер CAS 108347-85-9
Молекулярная формула C₁₁H₁₇N₂O₈P
Молекулярная масса 336.23 g/mol
Внешний вид Yellow to light yellow crystalline powder
Анализ (ВЭЖХ) ≥ 98.0% (high purity)
Purity (NAD⁺/NMN related) ≤ 5.0% oxidized forms

NMNH (Reduced Nicotinamide Mononucleotide) is the reduced form of nicotinamide mononucleotide (NMN). While NMN contains a nicotinamide ring in its oxidized state, NMNH features a dihydropyridine ring, making it chemically similar to NADH but at the mononucleotide level.

NMNH represents an emerging area of NAD⁺ precursor research. Unlike NMN (which must be converted to NAD⁺ via NMNAT enzymes), NMNH is believed to be more readily converted to NADH and may elevate cellular NAD⁺ levels through distinct metabolic pathways. Early research suggests potentially higher bioavailability and different tissue distribution compared to NMN.

C11H18N2NaO8P

Structural relationship:

Compound CAS No. Молекулярная масса Oxidation State Ring Structure
NMN (β-Nicotinamide Mononucleotide) 1094-61-7 334.22 g/mol Oxidized Pyridine ring
NMNH (Reduced NMN) 108347-85-9 336.23 g/mol Reduced Dihydropyridine ring
NAD⁺ 53-84-9 663.43 g/mol Oxidized Pyridine ring
NADH 606-68-8 665.44 g/mol Reduced Dihydropyridine ring

Приложения

1. Research & Development (Primary Market)

Приложение Описание Конечные пользователи
NAD⁺ metabolism research Studying alternative NAD⁺ biosynthesis pathways Academic research, universities
Aging & longevity research Comparative studies with NMN, NR, NADH Aging research institutes
Metabolic disease models In vitro and animal studies of energy metabolism Pharmaceutical R&D, CROs
Enzymology studies Substrate specificity of NMNAT, NRK, CD38 enzymes Biochemistry research

2. Comparative NAD⁺ Precursor Studies

Research Focus NMNH vs. NMN vs. NR vs. NADH
Bioavailability Which precursor elevates NAD⁺/NADH most efficiently?
Tissue distribution Does NMNH target different organs (liver, brain, muscle)?
Kinetics How quickly does each precursor elevate NAD⁺/NADH?
Stability Comparative stability under physiological conditions
Toxicity profile Safety assessment in animal models

3. Formulation Development (Early Stage)

Приложение Описание
Stabilization technology Developing stabilized NMNH for potential oral delivery
Liposomal encapsulation Enhancing stability and bioavailability
Analytical method development HPLC, LC-MS methods for NMNH quantification

Поставщик: LyvBio Co., Ltd.

LyvBio Co., Ltd. is a GMP-certified supplier of high-purity NMNH (Reduced NMN) for research and development applications.

Возможности поставок:

  • Assay (HPLC): ≥95.0% (standard), ≥98.0% (high purity)

  • Внешний вид: Yellow to light yellow crystalline powder

  • Форма: Lyophilized crystalline powder

  • Ежемесячная производительность: 500 г – 1 кг

  • Большие объемы: 100mg – 500g

  • Время выполнения: 3-5 дней (образцы), 10-15 дней (опт)

  • Документация: COA, MSDS, TDS, HPLC chromatogram, NMR (upon request), stability data

Обеспечение качества:

  • HPLC purity with UV detection (260 nm for oxidized forms, 340 nm for reduced forms)

  • Controlled storage and handling (-20°C freezer, inert atmosphere)

  • Stability-tested batches

📧 Спрашивает: info@lyvbio.com

NMNH vs. NMN vs. NR vs. NADH

Параметр NMNH NMN NR Chloride NADH
CAS No. 108347-85-9 1094-61-7 23111-00-4 606-68-8
Молекулярная масса 336.23 334.22 290.70 665.44
Oxidation state Reduced Oxidized Oxidized (precursor) Reduced
Внешний вид Yellow crystalline White powder White powder White powder
Primary role NADH precursor NAD⁺ precursor NAD⁺ precursor Electron donor (ATP)
Stability Very poor (requires -20°C, inert) Poor Moderate Very poor
Human clinical data None (research only) Limited Extensive (20+ trials) Limited
Regulatory status (USA) Not GRAS (research only) Not lawful as supplement* GRAS Not GRAS
Typical research dose Not applicable (preclinical) 250–500 mg 250–500 mg 5–50 mg
Primary market R&D / preclinical Research (limited supplement) Dietary supplements Dietary supplements

Часто задаваемые вопросы

Q: What is the difference between NMNH and NMN?
A: NMNH is the reduced form of NMN (dihydropyridine ring vs. pyridine ring). NMN is oxidized; NMNH is reduced. This structural difference gives NMNH distinct chemical properties (yellow color, different UV absorption, greater instability).

Q: Is NMNH a dietary supplement?
A: No. NMNH is a research compound. It is not GRAS, not approved as a dietary supplement in any major market, and has no human safety or efficacy data. LyvBio supplies NMNH for research and development purposes only.

Q: Why is NMNH yellow while NMN is white?
A: The yellow color is characteristic of the reduced dihydropyridine ring. NADH (reduced) is also pale yellow; NAD⁺ (oxidized) is white. This color difference is a quick visual indicator of oxidation state.

Q: Is NMNH more effective than NMN?
A: Unknown. Current research is limited to in vitro and early animal studies. No human data exist. NMNH is an emerging research area, not a proven NAD⁺ booster.

Q: How should NMNH be stored?
A: -20°C freezer, sealed, desiccated, under inert atmosphere (argon/nitrogen), protected from light. Failure to store properly results in rapid oxidation to NMN and other degradation products.

Q: What is the recommended dosage for research?
A: For in vitro studies: 10–100 µM. For animal studies: dosage varies by model. No human dosage exists. LyvBio does not provide dosing recommendations; researchers must determine appropriate concentrations.

Вопрос: Каков ваш минимальный объем заказа?
A: Research samples: 100mg–1g. Bulk research: 5g–100g. Lead time: 3–5 days (samples); 10–15 days (bulk). All NMNH shipments are temperature-controlled (dry ice or gel packs) with inert atmosphere packaging.

Свяжитесь с компанией «LyvBio Co., Ltd.».

📧 Электронная почта: info@lyvbio.com
🌐 Веб-сайт: https://www.lyvbio.com

ОСТАВАЙТЕСЬ НА СВЯЗИ

Запрос Цитировать

Наш адрес

Главная улица 280, Сиань, Шэньси, Китай

×